Epidemiologic studies of environmental exposures in Parkinson's disease

Journal of the Neurological Sciences

Volumn 262, Issue 1-2, 2007, Pages 37-44

  Elbaz, Alexis ^a,b   Tranchant, Christine ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Environment; Gene environment interaction; Parkinson's disease; Risk factors

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACID; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ASBESTOS; ATRAZINE; CHLOROACETAMIDE; COAL; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DITHIOCARBAMIC ACID; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; EPOXOMICIN; GLUTATHIONE TRANSFERASE; INSECTICIDE; NITRIC OXIDE SYNTHASE; ORGANOCHLORINE DERIVATIVE; ORGANOPHOSPHATE; PARAQUAT; PARKIN; PESTICIDE; SOLVENT; TRIAZINE DERIVATIVE; UNINDEXED DRUG; XENOBIOTIC AGENT;

AGE; AGING; ARTICLE; DEGENERATIVE DISEASE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIDEMIC; GENDER; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; LEWY BODY; MITOCHONDRIAL TOXICITY; NEUROTOXICITY; PARKINSON DISEASE; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; SMOKING;

CAUSALITY; COMORBIDITY; ENVIRONMENTAL ILLNESS; HAZARDOUS SUBSTANCES; HUMANS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; PARKINSON DISEASE; PESTICIDES; RISK FACTORS; SMOKING;

EID: 34548625019     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.06.024     Document Type: Article

References (100)

1. Bower J.H., Maraganore D.M., McDonnell S.K., and Rocca W.A. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52 (1999) 1214-1220
2. Hughes A.J., Daniel S.E., BenShlomo Y., and Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002) 861-870
3. de Rijk M.C., Rocca W.A., Anderson D.W., Melcon M.O., Breteler M.M., and Maraganore D.M. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 48 (1997) 1277-1281
4. Bower J.H., Maraganore D.M., McDonnell S.K., and Rocca W.A. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 15 (2000) 819-825
5. Twelves D., Perkins K.S.M., and Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 18 (2003) 19-31
6. Elbaz A., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 55 (2002) 25-31
7. de Rijk M.C., Tzourio C., Breteler M.M.B., Dartigues J.F., Amaducci L., LopezPousa S., et al. Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 62 (1997) 10-15
8. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (2000) S21-S23
9. MartinezMartin P. An introduction to the concept of "quality of life in Parkinson's disease". J Neurol 245 (1998) S2-S6
10. Parashos S.A., Maraganore D.M., O'Brien P.C., and Rocca W.A. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc 77 (2002) 918-925
11. Elbaz A., Bower J.H., Peterson B.J., Maraganore D., McDonnell S.K., Ahlskog J.E., et al. Survival study of Parkinson Disease in Olmsted County, Minnesota. Arch Neurol 60 (2003) 91-96
12. Chen H., Zhang S.M., Schwarzschild M.A., Hernan M.A., and Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord 21 (2006) 1002-1007
13. Morens D.M., Davis J.W., Grandinetti A., Ross G.W., Popper J.S., and White L.R. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 46 (1996) 1044-1050
14. Mayeux R., Marder K., Cote L.J., Denaro J., Hemenegildo N., Mejia H., et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 142 (1995) 820-827
15. Schoenberg B.S., Anderson D.W., and Haerer A.F. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 35 (1985) 841-845
16. Zhang Z.X., Roman G.C., Hong Z., Wu C.B., Qu Q.M., Huang J.B., et al. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365 (2005) 595-597
17. Schoenberg B.S., Osuntokun B.O., Adeuja A.O., Bademosi O., Nottidge V., Anderson D.W., et al. Comparison of the prevalence of Parkinson's disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology 38 (1988) 645-646
18. Lilienfeld D.E., Chan E., Ehland J., Godbold J., Landrigan P.J., Marsh G., et al. Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol 47 (1990) 731-734
19. Rocca W.A., Bower J.H., McDonnell S.K., Peterson B.J., and Maraganore D.M. Time trends in the incidence of parkinsonism in Olmsted County, Minnesota. Neurology 57 (2001) 462-467
20. Kuopio A.M., Marttila R.J., Helenius H., and Rinne U.K. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 52 (1999) 302-308
21. Checkoway H., and Nelson L.M. Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 10 (1999) 327-336
22. Cory-Slechta D.A., Thiruchelvam M., Barlow B.K., and Richfield E.K. Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect 113 (2005) 1263-1270
23. Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence?. Environ Health Perspect 113 (2005) 1234-1238
24. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62 (2005) 378-382
25. Hernan M.A., Takkouche B., CaamanoIsorna F., and GestalOtero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52 (2002) 276-284
26. Galanaud J.P., Elbaz A., Clavel J., Vidal J.S., Corrèze J.R., Alpérovitch A., et al. Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. Mov Disord 20 (2005) 181-189
27. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379 (1996) 733-736
28. Fowler J.S., Logan J., Wang G.J., and Volkow N.D. Monoamine oxidase and cigarette smoking. Neurotoxicology 24 (2003) 75-82
29. Quik M., and Kulak J.M. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 23 (2002) 581-594
30. Ross G.W., and Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 18 (2001) 797-806
31. Vieregge A., Sieberer M., Jacobs H., Hagenah J.M., and Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 57 (2001) 1032-1035
32. Ellenberg J.H. Differential postmorbidity mortality in observational studies of risk factors for neurologic disorders. Neuroepidemiology 13 (1994) 187-194
33. Menza M.A., Golbe L.I., Cody R.A., and Forman N.E. Dopamine-related personality traits in Parkinson's disease. Neurology 43 (1993) 505-508
34. Fujii C., Harada S., Ohkoshi N., Hayashi A., and Yoshizawa K. Cross-cultural traits for personality of patients with Parkinson's disease in Japan. Am J Med Genet 96 (2000) 1-3
35. Ishihara L., and Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord 21 (2006) 1066-1072
36. Wirdefeldt K., Gatz M., Pawitan Y., and Pedersen N.L. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann Neurol 57 (2005) 27-33
37. Tanner C.M., Goldman S.M., Aston D.A., Ottman R., Ellenberg J., Mayeux R., et al. Smoking and Parkinson's disease in twins. Neurology 58 (2002) 581-588
38. Scott W.K., Zhang F., Stajich J.M., Scott B.L., Stacy M.A., and Vance J.M. Family-based case-control study of cigarette smoking and Parkinson disease. Neurology 64 (2005) 442-447
39. Mellick G.D., Gartner C.E., Silburn P.A., and Battistuta D. Passive smoking and Parkinson's disease. Neurology 67 (2006) 179-180
40. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
41. Ascherio A., Zhang S.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50 (2001) 56-63
42. Ascherio A., Chen H., Schwarzschild M.A., Zhang S.M., Colditz G.A., and Speizer F.E. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60 (2003) 790-795
43. Barbeau A., Roy M., and Langston J.W. Neurological consequence of industrial exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Lancet 1 (1985) 747
44. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
45. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47 (1996) S153-S160
46. Barbeau A., Roy M., Bernier G., Campanella G., and Paris S. Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci 14 (1987) 36-41
47. Ritz B., and Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol 29 (2000) 323-329
48. Priyadarshi A., Khuder S.A., Schaub E.A., and Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 21 (2000) 435-440
49. Priyadarshi A., Khuder S.A., Schaub E.A., and Priyadarshi S.S. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 86 (2001) 122-127
50. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., and Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 (1998) 1346-1350
51. Nelson L.M., Van Den Eeden S.K., Tanner C.M., Efird J.T., and Bernstein A.L. Home pesticides exposure and the risk of Parkinson's disease (abstract). Neurology Suppl 3 (2000) S80
52. Firestone J.A., Smith-Weller T., Franklin G., Swanson P., Longstreth Jr. W.T., and Checkoway H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 62 (2005) 91-95
53. Frigerio R., Sanft K.R., Grossardt B.R., Peterson B.J., Elbaz A., Bower J.H., et al. WA.Chemical Exposures and Parkinson's Disease. A population-based case-control study. Mov Disord 21 (2006) 1688-1692
54. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 48 (1997) 1583-1588
55. Seidler A., Hellenbrand W., Robra B.P., Vieregge P., Nischan P., Joerg J., et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46 (1996) 1275-1284
56. Brown T.P., Rumsby P.C., Capleton A.C., Rushton L., and Levy L.S. Pesticides and Parkinson's disease-is there a link?. Environ Health Perspect 114 (2006) 156-164
57. Tuchsen F., and Jensen A.A. Agricultural work and the risk of Parkinson's disease in Denmark, 1981-1993. Scand J Work Environ Health 26 (2000) 359-362
58. Petrovitch H., Ross G.W., Abbott R.D., Sanderson W.T., Sharp D.S., Tanner C.M., et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 59 (2002) 1787-1792
59. Baldi I., Lebailly P., MohammedBrahim B., Letenneur L., Dartigues J.F., and Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol 157 (2003) 409-414
60. Ascherio A., Chen H., Weisskopf M.G., O'Reilly E.J., McCullough M.L., Calle E.E., et al. Pesticide exposure and Parkinson's disease. Ann Neurol 60 (2006) 197-203
61. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Amouyel P., et al. CYP2D6 polymorphism, pesticides exposure, and Parkinson's disease. Ann Neurol 55 (2004) 430-434
62. Stewart W.F., and Stewart P.A. Occupational case-control studies: I. Collecting information on work histories and work-related exposures. Am J Ind Med 26 (1994) 297-312
63. LeCouteur D.G., McLean A.J., Taylor M.C., Woodham B.L., and Board P.G. Pesticides and Parkinson's disease. Biomed Pharmacother 53 (1999) 122-130
64. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 (2004) 149-162
65. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
66. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 (2005) 484-494
67. Karen D.J., Li W., Harp P.R., Gillette J.S., and Bloomquist J.R. Striatal dopaminergic pathways as a target for the insecticides permethrin and chlorpyrifos. Neurotoxicology 22 (2001) 811-817
68. Zhang J., Fitsanakis V.A., Gu G.Y., Jing D.Q., Ao M.F., Amarnath V., et al. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem 84 (2003) 336-346
69. McCormack A.L., Thiruchelvam M., ManningBog A.B., Thiffault C., Langston J.W., CorySlechta D.A., et al. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10 (2002) 119-127
70. ManningBog A.B., McCormack A.L., Purisai M.G., Bolin L.M., and DiMonte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23 (2003) 3095-3099
71. Yumino K., Kawakami I., Tamura M., Hayashi T., and Nakamura M. Paraquat-and diquat-induced oxygen radical generation and lipid peroxidation in rat brain microsomes. J Biochem 131 (2002) 565-570
72. Uversky V.N., Li J., and Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 500 (2001) 105-108
73. Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58 (2002) 179-185
74. Thiruchelvam M., Richfield E.K., Goodman B.M., Baggs R.B., and Cory-Slechta D.A. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 23 (2002) 621-633
75. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57 (2005) 176-179
76. Tan E.K., Chan D.K., Ng P.W., Woo J., Teo Y.Y., Tang K., et al. Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 62 (2005) 460-464
77. Elbaz A., McDonnell S.K., Maraganore D.M., Strain K.J., Schaid D.J., Bower J.H., et al. Validity of family history data on PD: evidence for a family information bias. Neurology 61 (2003) 11-17
78. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7 (2006) 306-318
79. Hodgson E. In vitro human phase I metabolism of xenobiotics I: pesticides and related chemicals used in agriculture and public health, September 2001. J Biochem Mol Toxicol 15 (2001) 296-299
80. Hodgson E. In vitro human phase I metabolism of xenobiotics I: pesticides and related chemicals used in agriculture and public health, May 2003. J Biochem Mol Toxicol 17 (2003) 201-206
81. McCann S.J., Pond S.M., James K.M., and LeCouteur D.G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 153 (1997) 50-53
82. Deng Y., Newman B., Dunne M.P., Silburn P.A., and Mellick G.D. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann Neurol 55 (2004) 897
83. Rybicki B.A., Johnson C.C., Uman J., and Gorell J.M. Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov Disord 8 (1993) 87-92
84. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 48 (1997) 650-658
85. Fasano M., Bergamasco B., and Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 96 (2006) 909-916
86. Logroscino G., Marder K., Graziano J., Freyer G., Slavkovich V., Lojacono N., et al. Dietary iron, animal fats, and risk of Parkinson's disease. Mov Disord 13 Suppl 1 (1998) 13-6-13-16
87. Bower J.H., Maraganore D.M., Peterson B.J., McDonnell S.K., Ahlskog J.E., and Rocca W.A. Head trauma preceding PD - a case-control study. Neurology 60 (2003) 1610-1615
88. Maher N.E., Golbe L.I., Lazzarini A.M., Mark M.H., Currie L.J., Wooten G.F., et al. Epidemiologic study of 203 sibling pairs with Parkinson's disease - the GenePD study. Neurology 58 (2002) 79-84
89. Goldman S.M., Tanner C.M., Oakes D., Bhudhikanok G.S., Gupta A., and Langston J.W. Head injury and Parkinson's disease risk in twins. Ann Neurol 60 (2006) 65-72
90. Benedetti M.D., Maraganore D.M., Bower J.H., McDonnell S.K., Peterson B.J., Ahlskog J.E., et al. Menopause, hysterectomy, and estrogen in Parkinson's disease: an exploratory case-control study. Mov Disord 16 (2000) 830-837
91. Currie L.J., Harrison M.B., Trugman J.M., Bennett J.P., and Wooten G.F. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 61 (2004) 886-888
92. Popat R.A., Van Den Eeden S.K., Tanner C.M., McGuire V., Bernstein A.L., Bloch D.A., et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 65 (2005) 383-390
93. de Rijk M.C., Breteler M.M., den Breeijen J.H., Launer L.J., Grobbee D.E., van der Meche F.G., et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 54 (1997) 762-765
94. Park M., Ross G.W., Petrovitch H., White L.R., Masaki K.H., Nelson J.S., et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 64 (2005) 1047-1051
95. Hellenbrand W., Seidler A., Boeing H., Robra B.P., Vieregge P., Nischan P., et al. Diet and Parkinson's disease. I. A possible role for the past intake of specific foods and food groups - results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47 (1996) 636-643
96. Johnson C.C., Gorell J.M., Rybicki B.A., Sanders K., and Peterson E.L. Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol 28 (1999) 1102-1109
97. Chen H., Zhang S.M., Hernan M.A., Willett W.C., and Ascherio A. Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol 52 (2002) 793-801
98. Chen H., Zhang S.M., Hernan M.A., Willett W.C., and Ascherio A. Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol 157 (2003) 1007-1014
99. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 (2003) 1059-1064
100. Hernan M.A., Logroscino G., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006) 1097-1099